Piqray (alpelisib)

pCPA File Number: 21749

Negotiation Status:

Concluded without agreement

Indication(s):

Advanced or metastatic breast cancer, Hormone receptor-positive, HER2-negative, PIK3CA mutated, after disease progression following an endocrine-based regimen, in postmenopausal women and men (In combination with fulvestrant)

Sponsor/Manufacturer:

Novartis Pharmaceuticals Canada Inc.

CDA-AMC Project Number:

PC0247-000

pCPA Engagement Letter Issued:

2022-12-16

Negotiation Process Concluded:

2023-03-14